Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
Vertex Pharma’s Stock Has Tumbled. Earnings Will Stop the Pain.
31.10.2025 05:30
The growth for Vertex’s Journavax painkiller is just beginning to ramp up, given the potential size of the nonaddictive drug market.
1 Healthcare Stock with Impressive Fundamentals and 2 We Ignore
31.10.2025 04:40
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 9.8% gain for healthcare stocks has fallen short of the S&P 500’s 22.6% rise.
Eli Lilly and Co (LLY) Q3 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ...
31.10.2025 01:05
Eli Lilly and Co (LLY) reports a 54% revenue increase and raises guidance amid strong product performance and strategic growth initiatives.
Sector Update: Health Care Stocks Flat to Higher Premarket Thursday
30.10.2025 13:25
Health care stocks were flat to higher premarket Thursday, with the iShares Biotechnology ETF (IBB)
Novo Nordisk's bid for Metsera, Eli Lilly boosts revenue outlook
30.10.2025 13:25
Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Novo Nordisk's (NVO) bidding war with Pfizer (PFE) over who acquires Metsera (MTSR), Merck (MRK) cutting the higher end of its sales guidance, and Eli Lilly (LLY) raising its full-year revenue forecast after topping third quarter earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.
Eli Lilly Tops Earnings Forecasts and Raises Outlook as Zepbound and Mounjaro Sales Surge
30.10.2025 13:09
Strong demand for weight-loss and diabetes drugs boosts results and guidance.
Novo Nordisk A/S (NVO)’s Top Investor Decides to Take Control of its Board, Reports Reuters
30.10.2025 13:08
Novo Nordisk A/S (NYSE:NVO) is one of the Best Bargain Stocks to Buy in November. On October 22, Reuters reported that Novo Nordisk A/S (NYSE:NVO)’s top investor, the non-profit Novo Nordisk Foundation, decided to take control of the company’s board. It vowed a strong emphasis on the critical US market to fuel sales growth for Wegovy, and highlighted […]
Eli Lilly Raises 2025 Outlook as Third-Quarter Results Beat Estimates
30.10.2025 13:01
Eli Lilly (LLY) lifted its full-year outlook and reported third-quarter results above market expecta
Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker.
30.10.2025 12:37
Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.
Eli Lilly Blows Past Expectations On The Back Of Mounjaro, Zepbound
30.10.2025 12:24
Eli Lilly stock jumped early Thursday after the drugmaker easily topped third-quarter forecasts on the back of its two biggest drugs.
Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera
30.10.2025 12:20
Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US rival Pfizer which called the move "reckless".Pfizer called Novo Nordisk's offer a "reckless and unprecedented proposal".
Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings
30.10.2025 11:57
Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares higher.
Eli Lilly (LLY) Q3 Earnings and Revenues Surpass Estimates
30.10.2025 11:55
Lilly (LLY) delivered earnings and revenue surprises of +16.61% and +9.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Eli Lilly ramps up orforglipron production with $1.2bn Puerto Rico site expansion
30.10.2025 11:51
The Puerto Rico facility investment comes alongside Lilly’s construction of four “mega sites” in the US.
Eli Lilly raises annual revenue guidance amid strong weight-loss drug demand
30.10.2025 11:22
Investing.com - Eli Lilly has lifted its full-year financial forecasts, fueled by its mega-popular obesity treatments which helped the drugmaker deliver better-than-anticipated third-quarter results.
Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal
30.10.2025 11:13
Shares of Eli Lilly climbed Thursday after the drugmaker reported third-quarter earnings that blew past expectations. Eli Lilly shares were up 5.6% to $859 in premarket trading Thursday. Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate of $5.4 billion.
Eli Lilly (NYSE:LLY) Delivers Strong Q3 Numbers, Stock Soars
30.10.2025 11:04
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 53.9% year on year to $17.6 billion. The company’s full-year revenue guidance of $63.25 billion at the midpoint came in 2.6% above analysts’ estimates. Its non-GAAP profit of $7.02 per share was 18.6% above analysts’ consensus estimates.
Lilly: Q3 Earnings Snapshot
30.10.2025 10:53
INDIANAPOLIS (AP) — Eli Lilly and Co. (LLY) on Thursday reported third-quarter profit of $5.58 billion. The Indianapolis-based company said it had net income of $6.21 per share. Earnings, adjusted for one-time gains and costs, were $7.02 per share.
Eli Lilly's profits soar in Q3, sending the stock higher in premarket trading
30.10.2025 07:19
In Q3 2025, Eli Lilly reported adjusted net income of $6.31bn, compared with $1.06bn a year earlier, up a massive 493%. Adjusted EPS was $7.02 vs. $1.18 a year earlier.According to published data, net...